Plain-English translation of NCT06171607 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new type of ultrasound imaging called contrast-enhanced ultrasound (CEUS) that uses a special dye injected into your bloodstream to help doctors see breast masses more clearly. Researchers are using computer analysis to study how the dye moves through breast tissue, hoping to create a smarter tool that can tell whether a suspicious breast mass is cancer or not. The goal is to potentially help doctors avoid unnecessary biopsies by giving them a more accurate way to diagnose breast cancer early.
Currently, when doctors find a suspicious breast mass on ultrasound, many women need a biopsy to know for sure whether it's cancer—a procedure that can be stressful and isn't always necessary. This trial exists to see if adding contrast dye to ultrasound imaging, combined with computer learning, can give doctors better information before recommending a biopsy, which could spare some women from this invasive procedure.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will receive an injection of contrast dye (either Lumason or DEFINITY) into your vein, and then undergo a special ultrasound scan that lasts 60 to 90 minutes. During this time, the doctors will take multiple images as the dye travels through your breast tissue. The computer will then analyze these images to help determine whether your breast mass is benign or cancerous, potentially helping your doctor decide if you need a biopsy.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
United States